HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Steven P Weinstein Selected Research

rilonacept

8/2014Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.
7/2013Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.
2/2013Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.
10/2012Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.
10/2012Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
3/2012Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.
8/2008A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.
8/2008Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Steven P Weinstein Research Topics

Disease

5Gout
08/2014 - 03/2012
4Infections
06/2015 - 03/2012
4Injection Site Reaction
08/2014 - 08/2008
3Inflammation (Inflammations)
07/2014 - 08/2008
2Atopic Dermatitis (Atopic Eczema)
01/2016 - 07/2014
2Nasopharyngitis
01/2016 - 07/2014
2Cryopyrin-Associated Periodic Syndromes
08/2008 - 08/2008
1Rheumatoid Arthritis
06/2015
1Tuberculosis (Tuberculoses)
08/2014
1Opportunistic Infections (Opportunistic Infection)
08/2014
1Asthma (Bronchial Asthma)
07/2014
1Eczema
07/2014
1Pruritus (Itching)
07/2014
1Headache (Headaches)
07/2014
1Pain (Aches)
02/2013
1Gouty Arthritis
02/2013
1Hyperuricemia
03/2012
1Exanthema (Rash)
08/2008
1Arthralgia (Joint Pain)
08/2008
1Amyloidosis
08/2008
1Fever (Fevers)
08/2008

Drug/Important Bio-Agent (IBA)

8rilonaceptFDA Link
08/2014 - 08/2008
5Uric Acid (Urate)IBA
08/2014 - 03/2012
5Interleukin-1 (Interleukin 1)IBA
07/2013 - 08/2008
3Biomarkers (Surrogate Marker)IBA
07/2014 - 08/2008
3Allopurinol (Remid)FDA LinkGeneric
07/2013 - 03/2012
2Interleukin-4 (Interleukin 4)IBA
01/2016 - 07/2014
2dupilumabIBA
01/2016 - 07/2014
2Interleukin-13IBA
01/2016 - 07/2014
2Monoclonal AntibodiesIBA
01/2016 - 07/2014
2InterleukinsIBA
01/2016 - 02/2013
1sarilumabIBA
06/2015
1Methotrexate (Mexate)FDA LinkGeneric
06/2015
1Calcineurin InhibitorsIBA
07/2014
1GlucocorticoidsIBA
07/2014
1Indomethacin (Indometacin)FDA LinkGeneric
02/2013
1C-Reactive ProteinIBA
08/2008
1Interleukin-1beta (Interleukin 1 beta)IBA
08/2008
1Serum Amyloid A Protein (Serum Amyloid A)IBA
08/2008
1Pharmaceutical PreparationsIBA
08/2008

Therapy/Procedure

5Therapeutics
08/2014 - 03/2012
2Subcutaneous Injections
08/2014 - 10/2012
1Aftercare (After-Treatment)
01/2016